Endologix

Endologix develops and manufactures minimally invasive treatments for aortic disorders. Endologix's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.

IRVINE, Calif.--(BUSINESS WIRE)-- #AAA--The ChEVAS™ (Chimney EndoVascular Aneurysm Sealing) System from Endologix has been granted a Breakthrough Device Designation from the FDA.

Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System

IRVINE, Calif.--(BUSINESS WIRE)-- #AAA--Endologix has launched the ALTO™ Abdominal Stent Graft System in Europe for the treatment of patients with abdominal aortic aneurysm (AAA)

Endologix Launches ALTO™ Abdominal Stent Graft System in Europe

IRVINE, Calif.--(BUSINESS WIRE)--Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc.

Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System Outside of United States

Endologix (ELGXQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Endologix (ELGXQ) Q2 Earnings Expected to Decline

IRVINE, Calif.--(BUSINESS WIRE)--Transforming the treatment of aortic disorders, Endologix® Inc.

Endologix Receives CE Mark for ALTO Abdominal Stent Graft System

IRVINE, Calif.--(BUSINESS WIRE)--Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S.

Endologix Announces First Commercial Implant of ALTO Abdominal Stent Graft System & Official Start of U.S. Commercial Release

Shares of Endologix, Inc. (NASDAQ: ELGX), a manufacturer of medical devices for the treatment of aortic disorder, are moving to the downside Monday.

Why Shares of Medical Device Maker Endologix Are Cratering

Shares of Endologix Inc. ELGX, -2.77% plunged 41% toward a record low in premarket trading Monday, after the medical device maker filed for bankruptcy over the weekend, and announced a deal to be taken private by its largest creditor Deerfield Partners.

Endologix's stock plunges toward record low after bankruptcy filing

Endologix, Inc. (ELGX) CEO John Onopchenko on Q1 2020 Results - Earnings Call Transcript

Endologix (ELGX) delivered earnings and revenue surprises of -19.40% and 0.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Endologix (ELGX) Reports Q1 Loss, Tops Revenue Estimates

Investors need to pay close attention to Endologix (ELGX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Endologix (ELGX) Stock?

Endologix, Inc. (ELGX) CEO John Onopchenko on Q4 2019 Results - Earnings Call Transcript

Endologix (ELGX) delivered earnings and revenue surprises of 40.00% and -0.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Endologix (ELGX) Reports Q4 Loss, Misses Revenue Estimates

Endologix (ELGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Endologix (ELGX) Report Negative Earnings Next Week? What You Should Know

Endologix, Inc. (ELGX) CEO John Onopchenko on Q3 2019 Results - Earnings Call Transcript

Endologix (ELGX) delivered earnings and revenue surprises of 15.63% and 1.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Endologix (ELGX) Reports Q3 Loss, Tops Revenue Estimates

Endologix (ELGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endologix (ELGX) Expected to Beat Earnings Estimates: Should You Buy?

Endologix's (ELGX) CEO John Onopchenko on Q2 2019 Results - Earnings Call Transcript

Endologix (ELGX) delivered earnings and revenue surprises of 53.75% and 0.41%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Endologix (ELGX) Reports Q2 Loss, Tops Revenue Estimates

As of late, it has definitely been a great time to be an investor in Endologix, Inc. (ELGX).

Endologix, Inc. (ELGX) Shares March Higher, Can It Continue?

Endologix's (ELGX) CEO John Onopchenko on Q1 2019 Results - Earnings Call Transcript

Endologix (ELGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Endologix Stock (ELGX)